文献速递心脑血管急症重症综合管理与镇静镇痛

四因子与三因子凝血酶原复合物浓缩物在华法林相关颅内出血急诊管理中的比较

Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.
PubMed 文献 · Neurocrit Care · 2018-01-01
一句话结论多中心回顾性队列显示,四因子与三因子凝血酶原复合物浓缩物逆转华法林相关颅内出血的院内死亡率无统计学显著差异(OR 2.2,95%CI 0.59-9.4,p=0.26)。

该多中心回顾性队列研究纳入103例华法林相关颅内出血患者,63例接受四因子凝血酶原复合物浓缩物(PCC),其余接受三因子PCC。主要终点院内死亡率在四因子PCC组更高但无统计学显著性(OR 2.2,95%CI 0.59-9.4,p=0.26),格拉斯哥昏迷评分≤8分解释了大部分差异(OR 48,95%CI 14-219,p<0.001)。所有次要终点(30天死亡率、出院去向、ICU及住院自由天数、INR逆转、90天血栓栓塞事件)均无统计学显著差异。结论认为四因子PCC并未改善院内死亡率,次要临床结局同样无统计学显著性。

要点

  • 103例华法林相关颅内出血患者中63例接受四因子PCC,院内死亡率25%、30天死亡率35%。
  • 四因子PCC组院内死亡率更高但无统计学显著性(OR 2.2,95%CI 0.59-9.4,p=0.26)。
  • 格拉斯哥昏迷评分≤8分解释了四因子PCC组院内死亡率差异的大部分(OR 48,95%CI 14-219,p<0.001)。
  • 所有次要终点(30天死亡率、出院去向、ICU及住院自由天数、INR逆转、90天血栓栓塞事件)均无统计学显著差异。
  • 四因子PCC组血栓栓塞事件粗发生率较高(19% vs 10%),但无统计学显著性。

适用人群与场景

  • 华法林相关颅内出血患者,接受四因子或三因子PCC逆转治疗。
  • 中位年龄79岁(四分位间距73-84),中位就诊INR 2.7(2.2-3.3),51%为脑实质内出血。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入103例华法林相关颅内出血患者,63例接受四因子PCC。
  • 主要终点院内死亡率:四因子PCC组更高但无统计学显著性(OR 2.2,95%CI 0.59-9.4,p=0.26);GCS≤8分解释了大部分差异(OR 48,95%CI 14-219,p<0.001)。
  • 院内死亡率25%,30天死亡率35%;所有次要终点(30天死亡率、出院去向、ICU及住院自由天数、INR逆转、90天血栓栓塞事件)四因子PCC效应均无统计学显著性。
  • 血栓栓塞事件粗发生率四因子PCC组19% vs 三因子PCC组10%,无统计学显著性。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,四因子与三因子PCC在急诊逆转华法林相关颅内出血时院内死亡率无改善,次要临床结局同样无统计学显著性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Four-factor prothrombin complex concentrates (PCC) produce a more rapid and complete INR correction compared with 3-factor PCC in patients receiving warfarin. It is unknown if this improves clinical outcomes in the setting of intracranial hemorrhage (ICH).

METHODS: This multicenter, retrospective cohort study included patients presenting with warfarin-associated ICH reversed with either 4- or 3-factor PCC. The primary outcome was in-hospital mortality. Secondary outcomes were 30-day mortality, discharge location, intensive care unit (ICU) and hospital-free days, INR reversal, and thromboembolic (TE) events at 90 days. Each was analyzed using regression analysis. Continuous and binary outcomes were analyzed using linear and logistic regression, respectively, while ordinal regression was used for discharge location.

RESULTS: Of the 103 patients, 63 received 4-factor PCC. Median age was 79 years [interquartile intervals(IQI 73-84)], median presenting INR was 2.7 (2.2-3.3), and presenting ICH was intraparenchymal in 51% of patients. In-hospital and 30-day mortality were 25 and 35%, respectively. In-hospital mortality was greater among those who received 4-factor PCC, yet was not statistically significant (OR 2.2, 95% CI 0.59-9.4, p = 0.26), as having Glasgow Coma Scale (GCS) ≤8 explained most of the difference (OR 48, 95% CI 14-219, p <0.001). The effect of 4-factor PCC was not statistically significant in any of the secondary analyses. Crude rates of TE events were higher in the 4-factor PCC group (19 vs. 10%), though not significantly.

CONCLUSIONS: In-hospital mortality was not improved with the use of 4- versus 3-factor PCC in the emergent reversal of warfarin-associated ICH. Secondary clinical outcomes were similarly nonsignificant.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Fischer D, Sorensen J, Fontaine GV, et al. Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage. Neurocrit Care. 2018. PMID: 28612131. doi:10.1007/s12028-017-0374-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。